Skip to main content
SpringerLink
Log in

Hypertension as a Risk Factor for Heart Failure

  • Hypertension and the Heart (SD Solomon and O Vardeny, Section Editors)
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Hypertension remains a significant risk factor for development of congestive heart failure CHF), with various mechanisms contributing to both systolic and diastolic dysfunction. The pathogenesis of myocardial changes includes structural remodeling, left ventricular hypertrophy, and fibrosis. Activation of the sympathetic nervous system and renin-angiotensin system is a key contributing factor of hypertension, and thus interventions that antagonize these systems promote regression of hypertrophy and heart failure. Control of blood pressure is of paramount importance in improving the prognosis of patients with heart failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–e245. Hypertensive heart disease remains the major risk factor for various medical conditions.

    Article  PubMed  Google Scholar 

  2. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993;22(4 Suppl A):6A–13A.

    Article  CAS  PubMed  Google Scholar 

  3. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557–62.

    Article  CAS  PubMed  Google Scholar 

  4. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med. 1996;156(16):1789–96.

    Article  CAS  PubMed  Google Scholar 

  5. Perry Jr HM, Bingham S, Horney A, Rutan G, Sambhi M, Carmody S, et al. Antihypertensive efficacy of treatment regimens used in Veterans Administration hypertension clinics. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Hypertension. 1998;31(3):771–9.

    Article  CAS  PubMed  Google Scholar 

  6. Furberg CD, Yusuf S. Effect of drug therapy on survival in chronic heart failure. Adv Cardiol. 1986;34:124–30.

    CAS  PubMed  Google Scholar 

  7. Frohlich ED. An updated concept for left ventricular hypertrophy risk in hypertension. Ochsner J. 2009;9(4):181–90.

    PubMed Central  PubMed  Google Scholar 

  8. Raman SV. The hypertensive heart. An integrated understanding informed by imaging. J Am Coll Cardiol. 2010;55(2):91–6. Recognition of hypertensive disease has prognostic implications.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Berenji K, Drazner MH, Rothermel BA, Hill JA. Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol. 2005;289(1):H8–H16.

    Article  CAS  PubMed  Google Scholar 

  10. Verdecchia P, Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M, et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol. 2001;38(7):1829–35.

    Article  CAS  PubMed  Google Scholar 

  11. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol. 1995;25(4):879–84.

    Article  CAS  PubMed  Google Scholar 

  12. Tomanek RJ, Wessel TJ, Harrison DG. Capillary growth and geometry during long-term hypertension and myocardial hypertrophy in dogs. Am J Physiol. 1991;261(4 Pt 2):H1011–8.

    CAS  PubMed  Google Scholar 

  13. Lorell BH, Grossman W. Diastolic relaxation of the heart: the biology of diastole in health and disease. 2nd ed. Boston: Kluwer Academic Publishers; 1994. xiii, 348 p. p.

    Book  Google Scholar 

  14. Grimson KS. Total thoracic and partial to total lumbar sympathectomy and celiac ganglionectomy in the treatment of hypertension. Ann Surg. 1941;114(4):753–75.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81. Catheter-based renal denervation causes substantial and sustained blood-pressure reduction in patients with resistant hypertension.

    Article  PubMed  Google Scholar 

  16. Esler MD, Krum H, Schlaich M, Schmieder RE, Bohm M, Sobotka PA, et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126(25):2976–82. Renal denervation provides sustained drop in blood pressure in patients with resistant hypertension.

    Article  CAS  PubMed  Google Scholar 

  17. Esler M. In: Birkenhäger WH, editor. Handbook of hypertension. 25.

  18. Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J. 2012;33(9):1058–66.

    Article  CAS  PubMed  Google Scholar 

  19. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73(4):615–21.

    Article  CAS  PubMed  Google Scholar 

  20. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311(13):819–23.

    Article  CAS  PubMed  Google Scholar 

  21. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol. 1995;26(5):1257–63.

    Article  CAS  PubMed  Google Scholar 

  22. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990;66(4):883–90.

    Article  CAS  PubMed  Google Scholar 

  23. Hirsch AT, Pinto YM, Schunkert H, Dzau VJ. Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. Am J Cardiol. 1990;66(11):22D–30D. discussion D-2D.

    Article  CAS  PubMed  Google Scholar 

  24. Harrap SB, Dominiczak AF, Fraser R, Lever AF, Morton JJ, Foy CJ, et al. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation. 1996;93(6):1148–54.

    Article  CAS  PubMed  Google Scholar 

  25. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115(1):41–6.

    Article  PubMed  Google Scholar 

  26. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA. 1996;275(19):1507–13.

    Article  CAS  PubMed  Google Scholar 

  27. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Pozzi M, Morganti A, et al. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation. 1997;96(4):1173–9.

    Article  CAS  PubMed  Google Scholar 

  28. Wei CM, Lerman A, Rodeheffer RJ, McGregor CG, Brandt RR, Wright S, et al. Endothelin in human congestive heart failure. Circulation. 1994;89(4):1580–6.

    Article  CAS  PubMed  Google Scholar 

  29. Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol. 1993;71(7):602–4.

    Article  CAS  PubMed  Google Scholar 

  30. Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, et al. The heart in hypertension. N Engl J Med. 1992;327(14):998–1008.

    Article  CAS  PubMed  Google Scholar 

  31. Rame JE, Ramilo M, Spencer N, Blewett C, Mehta SK, Dries DL, et al. Development of a depressed left ventricular ejection fraction in patients with left ventricular hypertrophy and a normal ejection fraction. Am J Cardiol. 2004;93(2):234–7.

    Article  PubMed  Google Scholar 

  32. Milani RV, Drazner MH, Lavie CJ, Morin DP, Ventura HO. Progression from concentric left ventricular hypertrophy and normal ejection fraction to left ventricular dysfunction. Am J Cardiol. 2011;108(7):992–6. Approximately 13% of patients with concentric LV hypertrophy and normal ejection fraction progress to systolic dysfunction when followed up for three years.

    Article  PubMed  Google Scholar 

  33. Krishnamoorthy A, Brown T, Ayers CR, Gupta S, Rame JE, Patel PC, et al. Progression from normal to reduced left ventricular ejection fraction in patients with concentric left ventricular hypertrophy after long-term follow-up. Am J Cardiol. 2011;108(7):997–1001. In patients with concentric left ventricular hypertrophy, the progression of LVH from a normal LVEF to a low LVEF is infrequent (20%) during a long-term follow-up study.

    Article  PubMed  Google Scholar 

  34. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol. 2004;43(12):2207–15.

    Article  PubMed  Google Scholar 

  35. Janardhanan R, Desai AS, Solomon SD. Therapeutic approaches to diastolic dysfunction. Curr Hypertens Rep. 2009;11(4):283–91. Abnormalities of passive stiffness or active relaxation of the myocardium impair ventricular filling during diastole and may contribute to the development heart failure with preserved ejection fraction.

    Article  CAS  PubMed  Google Scholar 

  36. Mandinov L, Eberli FR, Seiler C, Hess OM. Diastolic heart failure. Cardiovasc Res. 2000;45(4):813–25.

    Article  CAS  PubMed  Google Scholar 

  37. Zile MR, Gaasch WH, Carroll JD, Feldman MD, Aurigemma GP, Schaer GL, et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation. 2001;104(7):779–82.

    Article  CAS  PubMed  Google Scholar 

  38. Zile MR. Heart failure with preserved ejection fraction: is this diastolic heart failure? J Am Coll Cardiol. 2003;41(9):1519–22.

    Article  PubMed  Google Scholar 

  39. Borbely A, van der Velden J, Papp Z, Bronzwaer JG, Edes I, Stienen GJ, et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation. 2005;111(6):774–81.

    Article  PubMed  Google Scholar 

  40. Phillips RA, Goldman ME, Ardeljan M, Arora R, Eison HB, Yu BY, et al. Determinants of abnormal left ventricular filling in early hypertension. J Am Coll Cardiol. 1989;14(4):979–85.

    Article  CAS  PubMed  Google Scholar 

  41. Eberli FR, Apstein CS, Ngoy S, Lorell BH. Exacerbation of left ventricular ischemic diastolic dysfunction by pressure-overload hypertrophy. Modification by specific inhibition of cardiac angiotensin converting enzyme. Circ Res. 1992;70(5):931–43.

    Article  CAS  PubMed  Google Scholar 

  42. Brilla CG, Matsubara L, Weber KT. Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. Hypertension. 1996;28(2):269–75.

    Article  CAS  PubMed  Google Scholar 

  43. Smith WM. Treatment of mild hypertension: results of a ten-year intervention trial. Circ Res. 1977;40(5 Suppl 1):I98–I105.

    CAS  PubMed  Google Scholar 

  44. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338(8778):1281–5.

    Article  CAS  PubMed  Google Scholar 

  45. Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens. 1987;5(5):561–72.

    Article  CAS  PubMed  Google Scholar 

  46. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90(4):1786–93.

    Article  CAS  PubMed  Google Scholar 

  47. Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens. 2008;21(5):500–8.

    Article  PubMed  Google Scholar 

  48. Borhani NO, Blaufox MD, Oberman A, Polk BF. Incidence of coronary heart disease and left ventricular hypertrophy in the Hypertension Detection and Follow-up Program. Prog Cardiovasc Dis. 1986;29(3 Suppl 1):55–62.

    Article  CAS  PubMed  Google Scholar 

  49. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens. 1992;5(2):95–110.

    PubMed  Google Scholar 

  50. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation. 2003;108(6):684–90.

    Article  CAS  PubMed  Google Scholar 

  51. Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation. 2001;104(11):1248–54.

    Article  CAS  PubMed  Google Scholar 

  52. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108(15):1831–8.

    Article  CAS  PubMed  Google Scholar 

  53. de Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH, et al. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol. 1994;23(6):1444–51.

    Article  PubMed  Google Scholar 

  54. Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol. 2001;37(4):1042–8.

    Article  CAS  PubMed  Google Scholar 

  55. Wachtell K, Palmieri V, Olsen MH, Gerdts E, Papademetriou V, Nieminen MS, et al. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. Circulation. 2002;106(2):227–32.

    Article  CAS  PubMed  Google Scholar 

  56. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292(19):2343–9. Antihypertensive therapy result in regression of electrocardiographic LVH and may improve prognosis.

    Article  CAS  PubMed  Google Scholar 

  57. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97(1):48–54.

    Article  CAS  PubMed  Google Scholar 

  58. Pierdomenico SD, Lapenna D, Cuccurullo F. Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension. Am J Hypertens. 2008;21(4):464–70.

    Article  PubMed  Google Scholar 

  59. Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens. 2006;24(11):2163–8.

    Article  CAS  PubMed  Google Scholar 

  60. Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press. 1998;7(3):176–83.

    Article  CAS  PubMed  Google Scholar 

  61. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA. 2006;296(10):1242–8.

    Article  CAS  PubMed  Google Scholar 

  62. Rials SJ, Wu Y, Xu X, Filart RA, Marinchak RA, Kowey PR. Regression of left ventricular hypertrophy with captopril restores normal ventricular action potential duration, dispersion of refractoriness, and vulnerability to inducible ventricular fibrillation. Circulation. 1997;96(4):1330–6. Regression of LVH with captopril normalizes the electrophysiological abnormalities of ventricular hypertrophy and reduces the vulnerability to ventricular fibrillation.

    Article  CAS  PubMed  Google Scholar 

  63. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991 Aug 1;325(5):293–302.

  64. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987 Jun 4;316(23):1429–35.

  65. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol. 2003;41(9):1529–38.

    Article  CAS  PubMed  Google Scholar 

  66. Dries DL, Strong MH, Cooper RS, Drazner MH. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol. 2002;40(2):311–7.

    Article  CAS  PubMed  Google Scholar 

  67. Heran BS, Musini VM, Bassett K, Taylor RS, Wright JM. Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev. 2012;4, CD003040. Adding an angiotensin receptor blocker in combination with an angiotensin-converting enzyme inhibitor does not reduce total mortality or total hospital admissions, but does increase withdrawals due to adverse effects, compared with angiotensin-converting enzyme inhibitors alone.

    PubMed  Google Scholar 

  68. Mizuno Y, Yoshimura M, Yasue H, Sakamoto T, Ogawa H, Kugiyama K, et al. Aldosterone production is activated in failing ventricle in humans. Circulation. 2001;103(1):72–7.

    Article  CAS  PubMed  Google Scholar 

  69. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17.

    Article  CAS  PubMed  Google Scholar 

  70. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21.

    Article  CAS  PubMed  Google Scholar 

  71. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349–55.

    Article  CAS  PubMed  Google Scholar 

  72. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777–81.

    Article  CAS  PubMed  Google Scholar 

  73. Investigation G. Digitalis. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525–33.

    Article  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Arun Kannan and Rajesh Janardhanan declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Section of Cardiology, Sarver Heart Center, University of Arizona College of Medicine, Tucson, AZ, USA

    Arun Kannan & Rajesh Janardhanan

  2. Section of Inpatient Medicine, 1501 N Campbell Ave, PO Box 245212, Tucson, AZ, 85724, USA

    Arun Kannan

  3. Sarver Heart Center, University of Arizona, 1501 N. Campbell Avenue, Box 245037, Tucson, AZ, 85724, USA

    Rajesh Janardhanan

Authors
  1. Arun Kannan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rajesh Janardhanan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rajesh Janardhanan.

Additional information

This article is part of the Topical Collection on Hypertension and the Heart

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kannan, A., Janardhanan, R. Hypertension as a Risk Factor for Heart Failure. Curr Hypertens Rep 16, 447 (2014). https://doi.org/10.1007/s11906-014-0447-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11906-014-0447-7

Keywords

Search

Navigation